TERN Terns Pharmaceuticals
- 5.900
- -0.240-3.91%
- 6.060
- +0.160+2.71%
Terns Pharmaceuticals News
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product
Optimistic Buy Rating for Terns Pharmaceuticals Amid Promising Clinical Progress and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
Buy Rating Affirmed for Terns Pharmaceuticals Amid Robust Financials and Promising Pipeline Prospects
Express News | HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Terns Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 -6.62% HC Wainwright & Co. → $5.5 Reiterates Neutral → Neutral 04/30/2024 -6.62% HC Wainwright
Hold Rating on Terns Pharmaceuticals Pending Clinical Trial Outcomes
Analysts Are Bullish on These Healthcare Stocks: Alphatec Holdings (ATEC), Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals | 10-Q: Quarterly report
Express News | Terns Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results
Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections
Express News | Terns Pharma Q1 2024 GAAP EPS $(0.30) Beats $(0.34) Estimate
Terns Pharmaceuticals: Runway Into 2026 >TERN
Terns Pharmaceuticals: Runway Into 2026 >TERN
Express News | Terns Pharmaceuticals Inc: Cash, Cash Equivalents and Marketable Securities of $241 Mln, Expected to Provide Runway Into 2026
Express News | Terns Pharmaceuticals Q1 Pretax Profit USD -22.276 Million Vs. Ibes Estimate USD -24.8 Million
Express News | Terns Pharmaceuticals Q1 Basic EPS USD -0.3
Express News | Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
Express News | Terns Pharmaceuticals Q1 Income From Operations USD -25.446 Million Vs. Ibes Estimate USD -27 Million
Express News | Terns Pharmaceuticals Q1 Operating Expenses USD 25.446 Million
Terns Pharmaceuticals Announces Leadership Changes
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of smal
Analysis
Price Target
No Data
